Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 15/20 | 0.60 |
| ▸ | EGFR | P00533 | 1/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.58 |
| ▸ | KDR | P35968 | 1/20 | 0.58 |
| ▸ | FLT3 | P36888 | 1/20 | 0.56 |
| ▸ | RET | P07949 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12411362 | 0.93 | MET (0.67) | METEGFREPHX2KDRFLT3 | |
| SCHEMBL12411326 | 0.93 | MET (0.63) | METEGFRKDRFLT3 | |
| SCHEMBL12411784 | 0.92 | KDR (0.58) | METEGFREPHX2KDRFLT3 | |
| SCHEMBL12411414 | 0.91 | MET (0.60) | METEGFRKDRFLT3 | |
| SCHEMBL12411511 | 0.90 | MET (0.54) | METEGFRKDRRET | |
| SCHEMBL12411484 | 0.90 | FLT3 (0.55) | METEGFRKDRFLT3RET | |
| SCHEMBL12411454 | 0.89 | FGFR2 (0.60) | METEGFRKDR | |
| SCHEMBL12411782 | 0.87 | MET (0.60) | METEGFREPHX2KDRFLT3 | |
| SCHEMBL1894001 | 0.86 | MET (0.60) | METEGFREPHX2KDRFLT3 | |
| SCHEMBL12411387 | 0.86 | KDR (0.59) | METKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973160-B2 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20100197911-A1 | Nitrogen-Containing Aromatic Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-05 | — | — | US | disclosed |
| US-7612092-B2 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-7253286-B2 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI CO., LTD (JP) | 2007-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197911-A1 | Nitrogen-Containing Aromatic Derivatives | GNG2, GCG, FRG1 | MET 1810/4885EGFR 790/4885EPHX2 1957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.